Status:
COMPLETED
Effects of Ulinastatin on Myocardial Protection and Blood Loss in Patients Undergoing Aortic Valve Replacement
Lead Sponsor:
Yonsei University
Conditions:
Abnormal Aortic Valve
Eligibility:
All Genders
20-75 years
Phase:
PHASE4
Brief Summary
According to TEG (thromboelastography), as maximum amplitude is increased the amount of bleeding and transfusion and Cardiac enzyme is reduced by using ulinastatin.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- 40% below of output of left ventricle
- tricuspid valve failure from moderate to severe
- urgent surgery required
- infectious endocarditis
Exclusion
Key Trial Info
Start Date :
June 1 2009
Trial Type :
INTERVENTIONAL
End Date :
April 1 2011
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00944385
Start Date
June 1 2009
End Date
April 1 2011
Last Update
May 27 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Severance Hospital
Seoul, South Korea, 120-752